Wuwei Feng1,2, Jasmine Wang3, Pratik Y Chhatbar1, Christopher Doughty3, Douglas Landsittel4, Vasileios-Arsenios Lioutas3, Steven A Kautz5,2, Gottfried Schlaug3. 1. Department of Neurology, MUSC Stroke Center, Medical University of South Carolina, Charleston, SC. 2. Department of Health Sciences and Research, Medical University of South Carolina, Charleston, SC. 3. Neuroimaging & Stroke Recovery Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 4. Section on Biomarkers and Prediction Modeling, Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 5. Ralph H. Johnson VA Medical Center, Charleston, SC.
Abstract
OBJECTIVE: The aim of this work was to investigate whether an imaging measure of corticospinal tract (CST) injury in the acute phase can predict motor outcome at 3 months in comparison to clinical assessment of initial motor impairment. METHODS: A two-site prospective cohort study followed up a group of first-ever ischemic stroke patients using the Upper-Extremity Fugl-Meyer (UE-FM) Scale to measure motor impairment in the acute phase and at 3 months. A weighted CST lesion load (wCST-LL) was calculated by overlaying the patient's lesion map on magnetic resonance imaging with a probabilistic CST constructed from healthy control subjects. Regression models were fit to assess the predictive value of wCST-LL and compared with initial motor impairment. RESULTS: Seventy-six patients (37 from cohort 1 and 39 from cohort 2) completed the study. wCST-LL as well as assessment of motor impairment (UE-FM) in the acute phase correlated with motor impairment (UE-FM) at 3 months in both cohort 1 (R(2) = 0.69 vs. R(2) = 0.67; p = 0.43) and cohort 2 (R(2) = 0.69 vs. R(2) = 0.62; p = 0.25). In the severely impaired subgroup (defined as UE-FM ≤ 10 at baseline), wCST-LL correlated with outcomes significantly better than clinical assessment (R(2) = 0.47 vs. R(2) = 0.11; p = 0.03). In the nonseverely impaired subgroup, stroke patients recovered approximately 70% of their maximal recovery potential. All stroke patients in both cohorts had poor motor outcomes at 3 months (defined as UE-FM ≤ 25) when wCST-LL was ≥ 7.0 cc (positive predictive value was 100%). INTERPRETATION: wCST-LL, an imaging biomarker determined in the acute phase, can predict poststroke motor outcomes at 3 months, especially in patients with severe impairment at baseline.
OBJECTIVE: The aim of this work was to investigate whether an imaging measure of corticospinal tract (CST) injury in the acute phase can predict motor outcome at 3 months in comparison to clinical assessment of initial motor impairment. METHODS: A two-site prospective cohort study followed up a group of first-ever ischemic strokepatients using the Upper-Extremity Fugl-Meyer (UE-FM) Scale to measure motor impairment in the acute phase and at 3 months. A weighted CST lesion load (wCST-LL) was calculated by overlaying the patient's lesion map on magnetic resonance imaging with a probabilistic CST constructed from healthy control subjects. Regression models were fit to assess the predictive value of wCST-LL and compared with initial motor impairment. RESULTS: Seventy-six patients (37 from cohort 1 and 39 from cohort 2) completed the study. wCST-LL as well as assessment of motor impairment (UE-FM) in the acute phase correlated with motor impairment (UE-FM) at 3 months in both cohort 1 (R(2) = 0.69 vs. R(2) = 0.67; p = 0.43) and cohort 2 (R(2) = 0.69 vs. R(2) = 0.62; p = 0.25). In the severely impaired subgroup (defined as UE-FM ≤ 10 at baseline), wCST-LL correlated with outcomes significantly better than clinical assessment (R(2) = 0.47 vs. R(2) = 0.11; p = 0.03). In the nonseverely impaired subgroup, strokepatients recovered approximately 70% of their maximal recovery potential. All strokepatients in both cohorts had poor motor outcomes at 3 months (defined as UE-FM ≤ 25) when wCST-LL was ≥ 7.0 cc (positive predictive value was 100%). INTERPRETATION: wCST-LL, an imaging biomarker determined in the acute phase, can predict poststroke motor outcomes at 3 months, especially in patients with severe impairment at baseline.
Authors: Cathy M Stinear; P Alan Barber; Peter R Smale; James P Coxon; Melanie K Fleming; Winston D Byblow Journal: Brain Date: 2007-01 Impact factor: 13.501
Authors: Matthew S Jeffers; Boris Touvykine; Allyson Ripley; Gillian Lahey; Anthony Carter; Numa Dancause; Dale Corbett Journal: J Neurosci Date: 2020-06-30 Impact factor: 6.167
Authors: Josep Puig; Gerard Blasco; Gottfried Schlaug; Cathy M Stinear; Pepus Daunis-I-Estadella; Carles Biarnes; Jaume Figueras; Joaquín Serena; Maria Hernández-Pérez; Angel Alberich-Bayarri; Mar Castellanos; David S Liebeskind; Andrew M Demchuk; Bijoy K Menon; Götz Thomalla; Kambiz Nael; Max Wintermark; Salvador Pedraza Journal: Neuroradiology Date: 2017-03-14 Impact factor: 2.804
Authors: Ying Zhou; Ruiting Zhang; Sheng Zhang; Shenqiang Yan; Ze Wang; Bruce C V Campbell; David S Liebeskind; Min Lou Journal: Eur Radiol Date: 2017-05-24 Impact factor: 5.315
Authors: Bokkyu Kim; Beth E Fisher; Nicolas Schweighofer; Richard M Leahy; Justin P Haldar; Soyoung Choi; Dorsa B Kay; James Gordon; Carolee J Winstein Journal: J Neurosci Methods Date: 2018-04-21 Impact factor: 2.390
Authors: Jessica M Cassidy; Anirudh Wodeyar; Jennifer Wu; Kiranjot Kaur; Ashley K Masuda; Ramesh Srinivasan; Steven C Cramer Journal: Stroke Date: 2020-04-17 Impact factor: 7.914